Document is current

Article History

Received: 19 June 2023

Accepted: 1 July 2023

First Online: 28 July 2023

Declarations

:

: Not applicable.

: Not applicable.

: Paolo A. Ascierto (PAA): <i>Employment or Leadership Position</i>: None; <i>Consultant/Advisory Role</i>: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna; <i>Stock Ownership</i>: None; <i>Research Funding</i>: Bristol-Meyers Squibb, Roche-Genentech, Pfizer, Sanofi; <i>Expert Testimony</i>: None; <i>Other Remuneration</i>: None. Sanjiv S. Agarwala (SSA): nothing to disclose. Allison Betof Warner (ABW): <i>Consulting or Advisory</i>: Iovance Biotherapeutics, Novartis, BluePath Solutions, Pfizer, Instil Bio, Lyell Immunopharma, Bristol-Myers Squibb/Medarex, Immatics; <i>Research Funding:</i> Iovance Biotherapeutics; <i>Travel, Accommodations, Expenses:</i> Iovance Biotherapeutic. Marc S. Ernstoff (MSE): no conflict to disclose. Bernard A. Fox (BAF): <i>Scientific Advisory Board (Advising/Consulting)</i>: Akoya/PerkinElmer, AstraZeneca/Definiens, Bristol-Myers Squibb, CanWell, Hookipa, Incyte, Macrogenics, NeoGenomics, PrimeVax (BOD, stock), Turnstone, UbiVac, Co-founder/CEO/stock, Ultivue; <i>Research Support</i>: Akoya/PerkinElmer, Bristol-Myers Squibb, Definies/AstraZeneca, Incyte, Macrogenics, NanoString, OncoSec Shimadzu, Viralytics/Merck. Thomas F. Gajewski (TFG): <i>Consultant/advisory boards</i>: Merck, Bayer, Jounce, Fog Pharma, Adaptimmune, Pyxis, Allogene, Catalym, Bicara, Samyang; <i>Research support</i>: BMS, Merck, Seattle Genetics, Evelo,Bayer, Aduro, Pyxis; <i>Intellectual property/licensing</i>: Aduro, Evelo, BMS; <i>Cofounder/shareholder:</i> Jounce, Pyxis. Jérôme Galon (JG): has patents associated with the immune prognostic biomarkers. JG is co-founder of HalioDx, a Veracyte company, and part-time employee of Veracyte. Immunoscore® a registered trademark owned by the National Institute of Health and Medical Research (INSERM) and licenced to Veracyte. Claus Garbe (CG): personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from NeraCare, personal fees from BMS, personal fees from Philogen, grants and personal fees from Sanofi, during the conduct of the study. Brian R. Gastman (BRG): consulting agreements with: Quest imaging, Castle Biosciences, Merck, BMS, Alkermes, NIT, Instill Bio and Iovance. Jeffrey E. Gershenwald (JEG): Consultant and/or advisory role: Merck, Regeneron, Syndax. Pawel Kalinski (PW): Ikena; Mersana; Molecular Templates; Immunicum. Michelle Krogsgaard (MK): <i>Consultant for:</i> Guidepoint Network and GLG; <i>Grant/Research support from</i>: Agenus, AgenTus Therapeutics, Inc., Merck & Company, Inc., Genentech/Roche, Biogen, Novartis; <i>Scientific Advisory Board member</i>: NexImmune. Rom S. Leidner (RSL): Incyte & Ubivac: support of this study; Celldex: research; Clinigen: research; Bristol-Myers-Squibb: research, travel, advisory. Roger S. Lo (RSLO): Pfizer (investigator initiated trial, honorarium); Merck, OncoSec (research funding); Pfizer, DayOne (research funding, pending). Alexander M. Menzies (AMM): has served on advisory boards for BMS, MSD, Novartis, Roche, Pierre Fabre, QBiotics. Olivier Michielin (OM): Personal financial interests: Honoraria as speaker, consultancy or advisory role: BMS, Roche, Amgen, MSD, Novartis, GSK, Pierre-Fabre; Stock ownership: None; Direct Research Funding: BMS, MSD, Merk and Amgen​. Institutional financial interests: Research Funding: BMS, MSD and Amgen. Poulikos I. Poulikakos (PIP): research funding from Black Diamond Therapeutics, Verastem Onc. Jeffrey S. Weber (JSW): I consult for Merck, Genentech, Astra Zeneca, GSK, Novartis, Nektar, Celldex, Incyte, Biond, Moderna, ImCheck, Sellas, Evaxion, Pfizer, Regeneron and EMD Serono and BMS for membership on Advisory Boards; I hold equity in Biond, Evaxion, OncoC4 and Instil Bio. I am on scientific advisory boards for CytoMx, Incyte, ImCheck, Biond, Sellas, Instil Bio OncoC4 and Neximmune; I am not a member of any speaker’s bureau; NYU, but not me personally, received research support from BMS, Merck, GSK, Moderna, Pfizer, Novartis and Astra Zeneca; Moffitt Cancer Center filed a patent on an IPILIMUMAB biomarker and on TIL preparation that I am named on, and Biodesix filed a PD-1 patent that I was named on. Corrado Caracò (CC): no conflict to disclose. Iman Osman (IO): no conflict to disclose. Igor Puzanov (IP): <i>Research Funding:</i> NIH/NCI P30CA016056 Cancer Center Support Grant Program Leader, 1.2 Calendar Months; Co<i>Csulting/Advisory</i>: Nouscom, Iovance, Nektar, Regeneron. Magdalena Thurin (MT): no conflict to disclose.